Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Gastric Cancer • Esophageal Cancer • Medical Oncology • Immunotherapy • Biologic Therapy/Immunobiology
What impacts your decisions regarding the use of immunotherapy in metastatic G/E/GEJ cancers overall in light of variations in FDA approval, guidelines, and trial data?
Do you go by FDA approval alone, or incorporate other data into your treatment decisions?
How do you view updated recent presentation of CM-649 OS data presented at ASCO GI 2022 and published analysis by Zhao et al?
Answer from: Medical Oncologist at Academic Institution
The decision really lies in balancing the likelihood of benefit against potential toxicity. Checkpoint inhibition is generally very well tolerated, but there are patients that I am hesitant to consider it, including patients with rheumatoid arthritis, inflammatory bowel disease, or other autoimmune ...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
FDA approval is helpful to convince insurance companies to provide approval for therapy, but I do incorporate clinical trial data into my treatment decisions. For instance, FDA allows nivolumab and chemotherapy for patients without prerequisite for PD-L1 status, I would not treat a patient with immu...
Answer from: Medical Oncologist at Academic Institution
This undoubtedly has become a hotly debated area in terms of whether all patients derive long-term survival benefit from first-line chemoimmunotherapy given exploratory subgroup analyses have not demonstrated survival benefit in PD-L1 CPS < 5 or < 1 subgroups. In addition, there have been firs...